QLS-111-FDC for Glaucoma

(Firecrest Trial)

This trial tests a new eye drop, QLS-111-FDC, to determine its safety and effectiveness in lowering eye pressure in individuals with open-angle glaucoma or ocular hypertension, conditions that can lead to vision loss. Researchers aim to compare this new treatment's safety and efficacy to latanoprost, an existing medication for high eye pressure. Individuals diagnosed with mild to moderate open-angle glaucoma or ocular hypertension and an eye pressure of at least 19 mmHg may qualify for this study. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, allowing participants to contribute to significant advancements in eye care.

The trial requires that you do not use other topical eye medications for 30 days before starting. It doesn't specify about other medications, but you should discuss with the trial team.

Research has shown that QLS-111-FDC, a treatment tested for glaucoma and high eye pressure, has promising safety results from earlier studies. These studies found that QLS-111, a component of the treatment, is safe and well-tolerated by patients. Patients did not report any serious side effects, indicating no harmful reactions occurred. Additionally, the treatment did not cause significant eye redness, a common issue with some treatments. Overall, based on current research, this combination treatment appears to be a safe option.¹²³⁴⁵

Unlike the standard treatment for glaucoma, which often includes medications like Latanoprost that lower eye pressure, QLS-111-FDC offers a new approach. Researchers are excited about QLS-111-FDC because it combines multiple active ingredients into a single ophthalmic solution, potentially enhancing effectiveness and convenience for patients. This novel formulation aims to provide better pressure control and longer-lasting effects, which could mean fewer side effects and improved management of glaucoma.

Research has shown that QLS-111-FDC may help lower eye pressure in people with open-angle glaucoma or ocular hypertension. In this trial, participants will receive either QLS-111-FDC or Latanoprost. Studies found that combining QLS-111 with latanoprost can reduce eye pressure by up to 3.6 mmHg more than latanoprost alone. This suggests it might be more effective at lowering eye pressure, which is crucial for treating these conditions. The treatment aids the eye's drainage system in relieving pressure. These findings suggest that QLS-111-FDC could be a strong option for managing eye pressure in affected individuals.²³⁵⁶⁷